You are herePharma News

Pharma News

Giant Hope for Type I Diabetic patients - Stem cells are converted to Insulin Secreting beta cells

(15th October, 2014); Harvard researchers announced on last Thursday that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated 3 million Americans at a cost of about $15 billion annually with human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells.

New Nano-Cocoons Drug Delivery System against Cancer Cells

Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

Cipla Medpro announces collaboration with world ’s largest generic company - Teva Pharma

(9th October, 2014); Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa , yesterday announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.

Government imposing ban on use of plastic containers in liquid oral preparations

(7th October, 2014); Now in the near future, you may not see liquid orals in plastic containers because central government prohibits use of Polyethylene Terephthalate or Plastic containers for primary packaging of drug formulations in certain cases.

Galderma Initiates U.S. Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgery

(6th October, 2014; Business Wire India); Galderma, a global healthcare company focused on dermatology, today announced that it has initiated a Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigating the safety and efficacy of Galderma’s internally developed liquid formulation of botulinum toxin in the setting of aesthetic dermatology and cosmetic surgery and will add to the existing Galderma neurotoxin franchise.

Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC

(6th October, 2014); Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).

Broad spectrum antibiotics associated with obesity risk in 2 or less year old children

(1st October, 2014); Think before prescribing broad spectrum antibiotics in children below 2 years of age. Researchers from Philadelphia published a report on last Monday states that the use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood.

Apollo Hospitals and Sanofi Announce Collaboration to Provide an Integrated Care Program in India for People with Diabetes

(30th September, 2014; Business Wire India); Apollo Hospitals and Sanofi today announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics.

CM’s Healthcare Schemes A Boon For Patients

(30th September, 2014; Business Wire India); For the Maharashtra government, addressing health issues ranks high on its list of priorities and the same is reflected through various policy interventions, innovative steps and strategies implemented to provide quality healthcare for all.

Fortis Wins Prestigious BMJ Award for Successful Antibiotic Review Program

(30th September, 2014; Business Wire India); Fortis Healthcare announced on last friday (26th sept) that Fortis Mulund, one of its major hospitals in Mumbai has been conferred the prestigious British Medical Journal (BMJ) Award for ‘The Medical Team of the Year 2014.’ The honour was bestowed on the hospital for its outstanding “Antibiotic Review Program – and Antibiotic Restriction Policy.”